Literature DB >> 19535103

Third-generation tension-free tape for female stress urinary incontinence.

Edoardo Tartaglia1, Giampaolo Delicato, Giulio Baffigo, Stefano Signore, Francesco Corvese, Alessandro Perla, Vincenzo Ferdinandi.   

Abstract

PURPOSE: We reviewed our experience with the TVT-Secur tension-free tape for stress urinary incontinence in females. We evaluated operative time, complications, the continence rate and patient satisfaction at followup. Ethics committee approval was not required.
MATERIALS AND METHODS: A total of 32 hammock-shaped tape interventions were performed between November 2006 and April 2008 at our hospital. All patients had stress urinary incontinence, which was pure in 20 and associated with prolapse of other pelvic organs in 12. Each patient underwent urogynecological assessment with urodynamic evaluation and performed a quality of life questionnaire. We excluded from analysis all patients with intrinsic sphincteric deficiency. Patients were followed for continence and satisfaction. Therapeutic failure was defined as persistent urinary stress incontinence affecting quality of life, as reported by patients and on clinical examination.
RESULTS: None of the 32 women had any surgical complication, postoperative pain or blood loss greater than 100 cc. Some minor complications were recorded and the sling eroded in 1 case. Urinary continence was achieved in all patients after surgery and at assessments 12 to 18 months later. All patients confirmed immediate satisfaction with continence and pain on the questionnaire.
CONCLUSIONS: TVT-Secur is a minimally invasive, safe and easy surgical technique for stress urinary incontinence in females. To compare this procedure to other tension-free techniques longer and more detailed followup is necessary in more patients. However, this tape may be associated with fewer complications.

Entities:  

Mesh:

Year:  2009        PMID: 19535103     DOI: 10.1016/j.juro.2009.04.027

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

1.  One-year results of a prospective randomized, evaluator-blinded, multicenter study comparing TVT and TVT Secur.

Authors:  Maria Andrada Hamer; Per-Göran Larsson; Pia Teleman; Christina Eten Bergqvist; Jan Persson
Journal:  Int Urogynecol J       Date:  2012-06-16       Impact factor: 2.894

2.  Short-term results of a prospective randomized evaluator blinded multicenter study comparing TVT and TVT-Secur.

Authors:  Maria Andrada Hamer; Per-Göran Larsson; Pia Teleman; Christina Etén-Bergqvist; Jan Persson
Journal:  Int Urogynecol J       Date:  2011-04-16       Impact factor: 2.894

3.  Comparison of three mid-urethral tension-free tapes (TVT, TVT-O, and TVT-Secur) in the treatment of female stress urinary incontinence: 1-year follow-up.

Authors:  Yi-jun Wang; Fei-ping Li; Qian Wang; Sen Yang; Xian-guo Cai; Ying-he Chen
Journal:  Int Urogynecol J       Date:  2011-05-13       Impact factor: 2.894

4.  Proper mesh placement using the outer cylinder of a ballpoint pen in the transobturator adjustable tape sling procedure for female stress urinary incontinence.

Authors:  Oh Seok Ko; Yu Seob Shin; Sang Deuk Kim; Myung Ki Kim
Journal:  Korean J Urol       Date:  2012-05-18

5.  Predictive factors that influence treatment outcomes of innovative single incision sling: comparing TVT-Secur to an established transobturator sling for female stress urinary incontinence.

Authors:  Eugene Hwang; Ju Hyun Shin; Jae Sung Lim; Ki Hak Song; Chong Koo Sul; Yong Gil Na
Journal:  Int Urogynecol J       Date:  2012-02-10       Impact factor: 2.894

6.  One-Year Surgical Outcomes and Quality of Life after Minimally Invasive Sling Procedures for the Treatment of Female Stress Urinary Incontinence: TVT SECUR(R) vs. CureMesh(R).

Authors:  Young Min Joo; Jin Ho Choe; Ju Tae Seo
Journal:  Korean J Urol       Date:  2010-05-19

Review 7.  Surgical management of female SUI: is there a gold standard?

Authors:  Ashley Cox; Sender Herschorn; Livia Lee
Journal:  Nat Rev Urol       Date:  2013-01-15       Impact factor: 14.432

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.